For instance, dual CAR‐T therapies targeting EGFRvIII on tumor cells alongside senescent cell markers like p16INK4a or Bcl‐2 may enhance anti‐tumor efficacy by reducing senescent cells that contribute to tumor growth and immunosuppression. Here, CDKN2A is linked to neoplasm.